Cargando…
P05 The impact of COVID-19 on antifungal stewardship in a UK tertiary teaching hospital: a review of prescribing practices and therapeutic drug monitoring of posaconazole
BACKGROUND: Posaconazole is a triazole antifungal licensed for the prevention of invasive fungal infections (IFI) in haemato-oncology patients and treatment of IFI where first-line therapy has failed. In January 2020 COVID-19 hit the UK, with many NHS services reduced to meet the unprecedented chall...
Autores principales: | Andreani, Adam, Tyler, Netta, Micallef, Christiane, Enoch, David, Wong, Vanessa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156010/ http://dx.doi.org/10.1093/jacamr/dlac053.005 |
Ejemplares similares
-
Dendrimer-based posaconazole nanoplatform for antifungal therapy
por: Tang, Shengzhuang, et al.
Publicado: (2021) -
Effect of antifungal stewardship on micafungin prescribing practices in intensive care units at a tertiary-care hospital
por: Arya, Radhika, et al.
Publicado: (2023) -
1136. Antifungal Prescribing Patterns among Hospitalized Children in the United States: Are There Opportunities for Antifungal Stewardship?
por: Eguiguren, Lourdes, et al.
Publicado: (2019) -
Using Behavior Change Theory to Identify Drivers and Barriers for Antifungal Treatment Decisions: A Case Study in a Large Teaching Hospital in the East of England, UK
por: Micallef, Christianne, et al.
Publicado: (2023) -
Effectiveness of Posaconazole in Recalcitrant Fungal Keratitis Resistant to Conventional Antifungal Drugs
por: Altun, A., et al.
Publicado: (2014)